Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial.
<h4>Purpose</h4>This study aims to compare the safety and efficiency of modified biweekly CAPOX and conventional triweekly CAPOX in high-risk stage II and stage III post-surgery colorectal (CRC) patients.<h4>Methods</h4>From July 25, 2018, to May 14, 2021, high-risk stage II...
Saved in:
| Main Authors: | Hangyu Zhang, Danyang Wang, Zhou Tong, Tao Xiang, Xudong Zhu, Lulu Liu, Yi Zheng, Peng Zhao, Weijia Fang, Wenbin Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0313472 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Risk factor of severe diarrhea and enterocolitis induced by CAPOX: a retrospective multicenter study
by: A. Teixeira, et al.
Published: (2024-12-01) -
Ongoing 5-year+ survival after multiple metastasectomies, followed by CAPOX plus bevacizumab, for metastatic colorectal cancer
by: Kozue Matsuishi, et al.
Published: (2020-06-01) -
Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial
by: Sheng Li, et al.
Published: (2024-12-01) -
Syndrome of inappropriate antidiuretic hormone secretion in a patient with colon cancer using CAPOX plus bevacizumab therapy: a case report
by: Masanobu Uchiyama, et al.
Published: (2025-07-01) -
Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
by: Yanrong Wang, et al.
Published: (2025-03-01)